Patents
Patents for G01N 33 - Investigating or analysing materials by specific methods not covered by groups (393,632)
10/2005
10/13/2005WO2005094913A1 Generation of nitric oxide in situ at substrate/blood interfaces and nitric oxide sensor for detecting nitrosothiols
10/13/2005WO2005094909A1 Integrated control and distribution system for the decontamination of large volume, convoluted configuration spaces
10/13/2005WO2005094900A1 Preventive and/or remedy for cancer
10/13/2005WO2005094890A1 Composition for increasing body height
10/13/2005WO2005094887A1 sFRP EXPRESSION POTENTIATING AGENT
10/13/2005WO2005094886A1 Methods of inducing differentiation of regulatory t-cells and proliferating the same with gpi anchor protein agonist and medicinal composition therefor
10/13/2005WO2005094876A1 Diagnostics and therapeutics for diseases associated with p21 (cdkn1a)-activated kinase 2 (pak2)
10/13/2005WO2005094869A1 Compositions and methods for improved mucus function
10/13/2005WO2005094866A1 Adiponectin expression inducer and utilization of the same
10/13/2005WO2005094863A1 Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and decting protease inhibitors
10/13/2005WO2005094810A2 Novel pharmaceutical compositions
10/13/2005WO2005094675A1 Arrangement for analysing respiratory gases
10/13/2005WO2005094571A1 Genetically modified hetero animal and method of measuring exocytosis using the animal
10/13/2005WO2005094539A2 Reagents, methods and kits for the universal rapid immuno-detection
10/13/2005WO2005094533A2 Trail-r as a negative regulator of innate immune cell responses
10/13/2005WO2005094476A2 High throughput electrophysiology system
10/13/2005WO2005094467A2 Methods for reducing the range in concentrations of analyte species in a sample
10/13/2005WO2005094422A2 Angiocidin fragments and uses thereof in clinical assays for cancer and other diseases
10/13/2005WO2005094393A2 Methods and processes for attaching compounds to matrices
10/13/2005WO2005094391A2 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN
10/13/2005WO2005094382A2 A flow cytometric method and kit for metal-induced sensitivity
10/13/2005WO2005094381A2 Universal shotgun assay
10/13/2005WO2005094363A2 System, method and software arrangement for bi-allele haplotype phasing
10/13/2005WO2005094357A2 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
10/13/2005WO2005094348A2 Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
10/13/2005WO2005094324A2 Mixed cell diagnostic systems
10/13/2005WO2005094263A2 Methods of determining the prognosis and treatment of subjects with colon cancer
10/13/2005WO2005094259A2 Leptin binding domain compositions and methods thereto
10/13/2005WO2005094221A2 Nanostructures with electrodeposited nanoparticles
10/13/2005WO2005094219A2 Unique chromosomal sequence of bacillus anthracis and methods of making and using thereof including real-time pcr assays
10/13/2005WO2005094200A2 Biomarkers for differentiating between type 2 and type 2 diabetes
10/13/2005WO2005094188A2 Method of invasiveness control and use of adiponectin
10/13/2005WO2005094187A2 Labeling substance and chimera substance, process for preparing these substances, and method of biosubstance trapping, structural analysis or/and identification with use of the labeling substance
10/13/2005WO2005094159A2 Methods of identifying neoplasm-specific antibodies and uses thereof
10/13/2005WO2005085851A3 Granulocyte subtype-selective receptors and ion channels and uses thereof
10/13/2005WO2005083426A3 Method, chip, device and integrated system for detection biological particles
10/13/2005WO2005083391A9 Method, chip, device and system for collection of biological particles
10/13/2005WO2005078439A3 Wound meter
10/13/2005WO2005078438A3 Use of two-photon excited fluorescence in assays of clinical chemistry analytes
10/13/2005WO2005073363A8 An analysis chip, an apparatus comprising the chip, the chip test kit and the measurement method thereof
10/13/2005WO2005072145A3 Methods and systems for point of care bodily fluid analysis
10/13/2005WO2005067648A3 Multiplex spatial profiling of gene expression
10/13/2005WO2005067644A3 Conjugated small molecules
10/13/2005WO2005066630A3 Agents for and method of quantifying binding
10/13/2005WO2005065328A3 Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
10/13/2005WO2005062972A3 Treatment of cancer with novel anti-il 13 monoclonal antibodies
10/13/2005WO2005062055A3 Methods for detecting neoplasia and markers thereof
10/13/2005WO2005058452A3 Purification system
10/13/2005WO2005058352A3 Treatment of rheumatoid arthritis with galectin-3 antagonists
10/13/2005WO2005057199A8 Multiparameter system for environmental monitoring
10/13/2005WO2005056689A3 Cyanine dye compounds
10/13/2005WO2005033695A3 Digital imaging of single radial immunodiffusion assays
10/13/2005WO2005029043A3 Rho antibody and tag to purify cell surface proteins
10/13/2005WO2005027713A3 Compositions, splice variants and methods relating to colon specific genes and proteins
10/13/2005WO2005026741B1 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
10/13/2005WO2005026689A9 Immunoassay device with immuno-reference electrode
10/13/2005WO2005019801A3 Method for rapid identification of molecules with functional activity towards biomolecular targets
10/13/2005WO2005019474A3 Human autism susceptibility gene and uses thereof
10/13/2005WO2005014788A3 Tssk4: a human testis specific serine/threonine kinase
10/13/2005WO2005012506A3 Extended primary retinal cell culture and stress models, and methods of use
10/13/2005WO2005010205A3 Biomarkers fo aggrecanase activity
10/13/2005WO2004109280A3 System and method for multidimensional evaluation of combinations of compositions
10/13/2005WO2004104176A3 Method for the identification of inhibitors of ornithine carbamoyltransferase, ketol-acid reductoisomerase, and fungal pathogenicity-conferring gene as antibiotics
10/13/2005WO2004054436A3 Calcium-independent phospholipase a2 induces ischemic ventricular arrhythmias and decreases infarction size
10/13/2005WO2004008279A3 Computer user interface facilitating acquiring and analyzing of biological specimen traits
10/13/2005WO2003099779A3 Hemipteran muscarinic receptor
10/13/2005WO2002014467A9 Cng2b: a putative human cyclic nucleotide-gated ion channel
10/13/2005US20050229265 Insect ammunition vectors and methods of use to identify pesticide targets
10/13/2005US20050229260 Compound screens relating to insulin deficiency or insulin resistance
10/13/2005US20050228808 Real time data integration services for health care information data integration
10/13/2005US20050228604 Method and apparatus for calibrating a frequency domain reflectometer
10/13/2005US20050228596 Gas sensor, fuel cell system employing it, and automobile
10/13/2005US20050228595 Processors for multi-dimensional sequence comparisons
10/13/2005US20050228594 Quantitative measurements of concentration and solubility using Raman spectroscopy
10/13/2005US20050228592 Method and device for partitioning a molecule
10/13/2005US20050228591 Kernels and kernel methods for spectral data
10/13/2005US20050228310 Sampling device
10/13/2005US20050228169 Polypeptide binding to human syntaxin 1a
10/13/2005US20050228053 Atamestane and toremifene dosage forms and kits for use treating breast cancer
10/13/2005US20050227984 Drugs for improving the prognosis of brain injury and a method of screening the same
10/13/2005US20050227941 Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
10/13/2005US20050227918 Method for assaying susceptibility to cancer therapy in a subject by assaying for tumors of P53
10/13/2005US20050227917 Gene products differentially expressed in cancerous cells and their methods of use II
10/13/2005US20050227916 Administering carrier molecule such as albumin conjugated to mannose-6-phosphate; particularly targeting Hepatic Stellate Cells (HSC); glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, Crohn's disease, colitis ulcerosa, glomerulonephritis and sepsis; diagnosis
10/13/2005US20050227374 Label-free high-throughput optical technique for detecting biomolecular interactions
10/13/2005US20050227373 Method and device for high sensitivity detection of the presence of dna and other probes
10/13/2005US20050227372 Diagnostic test kit
10/13/2005US20050227371 Hybrid phase lateral flow assay
10/13/2005US20050227370 Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays
10/13/2005US20050227369 Rapid analysis of functional fluids
10/13/2005US20050227368 Contacting the sample with a trialkylsiloxylated organic compound (e.g., estradiol, peptide)that becomes desilylated in the presence of hydrofluoric acid or fluoride, and detecting and/or measuring the appearance of the desilylated organic compound, or the disappearance of the silylated organic compound
10/13/2005US20050227367 Solvent extraction the blood with acetonitrile and zinc sulfate, centrifuging; nonhydrolysis in plasma, storage stability; quantitative analysis using liquid chromatography
10/13/2005US20050227365 8-Hydroxyquinoline tripodal metal ion probes
10/13/2005US20050227363 Methods of monitoring rinsing solutions and related systems and reagents
10/13/2005US20050227362 Illuminating droplet monitoring location along each of one or more droplet travel paths with a respective beam of light; in response to backscatter reflection from a droplet passing through respective beam of light at respective droplet monitoring location, causing an increase in amplitude, monitoring
10/13/2005US20050227361 Method for investigating the thrombocyte function of the blood
10/13/2005US20050227359 A conditioning buffer or osmolality adjuster, a lytic quaternary ammonium surfactant, a fixative, and an ethoxylated alkyl phenol or an ethoxylated alkyl alcohol; quality control in hematology
10/13/2005US20050227351 Methods and compound protein molecules used for inducing cytotoxic cell-mediated immune response in a mammal against a pathogenic cell
10/13/2005US20050227350 Device and method for studying cell migration and deformation
10/13/2005US20050227310 Fluorescence activated cell sorting using caged fluorescent molecule is selected from the group consisting of N-(DMNB-caged fluorescein)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine or 5-carboxyfluorescein-bis-(5-carboxymethoxy-2-nitrobenzyl) ether-alanine-carboxamide, succinimidyl ester